The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease

Completed · Phase 2

Conditions studied: Parkinson's Disease

In brief

To determine the effects of the NMDA antagonist, CP-101,606, in subjects with Parkinson's Disease

Key facts

Study ID

NCT00163085

Run by

Pfizer

People needed

12

Starts

2005-05-01

Expected to finish

2006-01-01

Last updated by the study team

2006-09-22

Who can join

Age: 30 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 30- 80-year-old PD patients (UK Parkinson's Disease Brain Bank criteria) with a Hoehn \& Yahr stage score of 2-5 in the "off" state.

You may not qualify if…

• Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).

Where it is running

• Pfizer Investigational Site — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.